<?xml version='1.0' encoding='iso-8859-1'?>
<newsitem date="1996-12-18" id="root" itemid="264932" xml:lang="en">
<title>USA: Genelabs, DuPont-Merck in gene drug pact.</title>
<headline>Genelabs, DuPont-Merck in gene drug pact.</headline>
<dateline>REDWOOD CITY, Calif. 1996-12-18</dateline>
<text>
<p>Genelabs Technologies Inc said Wednesday that it has signed a research and license agreement with DuPont Merck, a joint venture of DuPont Co and Merck and Co Inc,  to jointly develop small molecule gene-regulating drugs.</p>
<p>Genelabs said the agreement provides research funding, a modest up-front payment, payments for milestones reached for each gene target and royalties for successful products. If all milestones were met, each gene target could produce about $20 million in payments to Genelabs, excluding potential royalties, the company said.</p>
</text>
<copyright>(c) Reuters Limited 1996</copyright>
<metadata>
<dc element="dc.date.created" value="1996-12-18" />
<dc element="dc.publisher" value="Reuters Holdings Plc" />
<dc element="dc.date.published" value="1996-12-18" />
<dc element="dc.source" value="Reuters" />
<dc element="dc.creator.location" value="REDWOOD CITY, Calif." />
<dc element="dc.creator.location.country.name" value="USA" />
<dc element="dc.source" value="Reuters" />
</metadata>
</newsitem>